Core Insights - Clarivate (CLVT) is a data intelligence company with a share price of $2.64 and a market cap of $1.67 billion, generating significant free cash flow and focusing on its core data assets in intellectual property and academic research [1] Financial Performance - In 2025, Clarivate generated $628.5 million in operating cash flow despite a net loss of $201.1 million, primarily due to $757.2 million in depreciation and amortization from past acquisitions [1] - The company reported free cash flow of $365.3 million for the full year and is guiding for $365 million to $435 million in 2026 [1] Strategic Initiatives - Clarivate is actively selling its Life Sciences and Healthcare segment to reduce its $4.47 billion debt load, with CEO Matti Shem Tov emphasizing the importance of this move for focusing on the A&G and IP market [1] - The sale proceeds from the Life Sciences and Healthcare segment could significantly improve the company's leverage situation [1] AI Integration - Clarivate views AI as an amplifier of its business model rather than a threat, integrating its regulatory intelligence platform with Anthropic's Claude to enhance its offerings [1] - The company maintains a strong revenue mix, with 97% coming from proprietary solutions and 88% being recurring revenue, creating a competitive moat [1] Market Position - Despite being largely unnoticed by mainstream investors, Clarivate's data assets are critical for researchers, patent attorneys, and pharmaceutical scientists, positioning the company as an essential player in its niche [1] - The stock has declined by 39% over the past year, with future performance dependent on the outcome of the LS&H sale, the pace of deleveraging, and the impact of AI on its business [1]

Summary of Clarivate's Earnings Call Company Overview - **Company**: Clarivate - **Industry**: Information Services - **Business Segments**: - Intelligence Solutions (over 50% of services) - Workflow Solutions (SaaS) - Tech-Enabled Services (primarily in Intellectual Property) [3][4] Key Business Segments - **Academia and Government**: Accounts for about 50% of business; serves 99% of the world's top 400 institutions [4] - **Intellectual Property**: Represents about one-third of business; serves in-house legal departments and law firms [5] - **Life Sciences and Healthcare**: Provides solutions to top pharma and med tech companies [5] Financial Performance Highlights - **Annual Contract Value (ACV)**: Growth improved from below 1% in 2024 to nearly 2% in 2025; guidance for 2026 is 2%-3% growth [7][8] - **Organic Recurring Revenue Growth**: Expected to accelerate from 0.5% in 2024 to between 1% and 2% in 2025 [9] - **Adjusted EBITDA**: Over $1 billion reported last year; expected profit margin expansion of 200 basis points by 2026 [10] - **Free Cash Flow**: Generated $365 million last year; anticipated to grow to about $400 million this year [11] Strategic Initiatives - **Divestiture of Life Sciences Business**: Aimed at focusing on higher growth segments (A&G and IP) and improving balance sheet quality [12][13] - **Value Creation Plan**: Focus on business model optimization, enhancing sales execution, accelerating innovation, and conducting a strategic review [17][18] - **Recurring Revenue Focus**: Shift from transactional to recurring revenue, aiming for 90% recurring revenue [37][38] AI and Innovation - **AI Integration**: Significant investments in AI across products, including research assistants and workflow agents [20][21] - **Web of Science**: Launch of AI-native platform to enhance analytics and research capabilities [26] - **Efficiency Improvements**: Independent studies show significant efficiency gains from AI implementations [27] Market Dynamics - **A&G Segment**: Improvement in renewal rates and contract value; strong funding for academic research expected to continue [42][43] - **IP Segment Growth Drivers**: Anticipated growth in patent filings due to sustained AI innovation; global patents in force have shown healthy growth [48][50] Capital Allocation - **Deleveraging Focus**: Plans to use free cash flow primarily for debt repayment; potential proceeds from the LS&H sale will also support this [55][56] Future Outlook - **Success Metrics for 2026**: Improved customer engagement with AI solutions, achievement of financial objectives, and continued organic growth in ACV and recurring revenue [57]

Core Insights - HG Vora Capital Management sold all 11,125,000 shares of Clarivate, resulting in a net position change of $42.61 million [2][6] Company Overview - Clarivate's stock price is $2.45, with a market capitalization of $1.6 billion and a revenue of $2.50 billion [4] - The company reported a net income of -$396 million [4] - Clarivate provides structured information and analytics, supporting research, intellectual property, and brand management through a subscription-driven model [5][8] Financial Performance - In 2025, Clarivate generated $2.46 billion in revenue, a decrease from $2.56 billion in 2024, with free cash flow of $365.3 million [10] - Organic annualized contract value increased by 1.8%, and recurring revenue now constitutes 88% of total sales, indicating improved revenue quality [10] Market Position and Strategy - Clarivate's shares have decreased by 42% over the past year, underperforming the S&P 500, which rose by about 16% in the same period [7] - The company is undergoing a strategic reset, with plans to explore the sale of its Life Sciences segment to reduce its total debt of $4.47 billion [10] - Clarivate is viewed as a restructuring story, with potential for attractive pricing if recurring revenue growth and deleveraging accelerate [11]

Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [18] - Q4 net income improved by $195 million year-over-year to $3 million, and full-year net income improved by $436 million, primarily due to the absence of prior year impairment charges [18] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [18] - Operating cash flow for Q4 was $160 million, reflecting a $19 million improvement compared to the previous year [19] - Free cash flow for the full year reached $365 million, representing approximately 2% growth over the prior year [22] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [12] - The Intellectual Property business saw a 270 basis point year-over-year improvement in annuities revenue, indicating stronger execution [15] - Life Sciences & Healthcare reported consistent quarterly ACV growth, with 11,000 global active users leveraging AI research assistants [15] Market Data and Key Metrics Changes - The company expects organic annual contract value growth of 2%-3% for 2026, an acceleration from previous years [16] - Recurring organic revenue is targeted to grow by 1%-2% in 2026, an improvement of nearly 100 basis points compared to the previous year [16] - The company anticipates a modest foreign exchange translation benefit of $10 million for the year [26] Company Strategy and Development Direction - The company is focused on selling its Life Sciences & Healthcare business to enhance value creation and strengthen its balance sheet [6][12] - The strategy emphasizes AI as an amplifier of existing business models rather than a disruption, with 97% of revenue derived from proprietary solutions [7][8] - The company plans to continue investing in AI innovations and has launched multiple AI-powered products to enhance customer workflows [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, citing strong cash generation and stable revenue retention rates of 93% [5] - The outlook for 2026 includes expectations for continued improvement in key financial metrics and a focus on maximizing shareholder value through disciplined capital allocation [17] - Management acknowledged market concerns regarding AI disruption but emphasized the proprietary nature of their offerings as a competitive advantage [7] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to allow for greater focus on the A&G and IP markets [6] - The company has successfully transitioned its business model towards a more predictable subscription-based model, increasing organic recurring revenue mix to 88% [11] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management indicated that they continue to use AI to protect and grow subscription revenue, with various pricing models based on institution size [34][35] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with significant value derived from curation and integration into customer workflows [42][43] Question: Considerations for selling Life Sciences and Healthcare business - Management stated that the decision was part of a broader value creation plan aimed at enhancing operational focus and shareholder value [50][51] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the IP and A&G segments, indicating potential for further collaboration [55][56] Question: Returning IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing improvements in annuities revenue and ongoing product innovation [61][63] Question: Capital allocation priorities - Management emphasized a focus on deleveraging while also considering stock buybacks, balancing between debt repayment and shareholder returns [67][68] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [71][72]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [18] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [18] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [18] - Operating cash flow for Q4 was $160 million, reflecting a $19 million improvement year-over-year [19] - Free cash flow for the full year reached $365 million, representing approximately 2% growth over the prior year [22] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now coming from proprietary solutions [12] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [15] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [15] Market Data and Key Metrics Changes - The company expects organic annual contract value growth of 2%-3% for 2026, an acceleration from previous years [16] - Recurring organic revenue is targeted to grow by 1%-2% in 2026, an improvement of nearly 100 basis points compared to the previous year [16] - The company anticipates a modest foreign exchange translation benefit of $10 million for the year [26] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance value creation and strengthen its balance sheet [6][12] - The strategy emphasizes AI as an amplifier of existing business models rather than a disruption, with 97% of revenue derived from proprietary assets [7][8] - The company aims to optimize its business model and improve sales execution, with a focus on innovation and product development [11][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve 10% free cash flow growth in 2026, supported by strong cash generation and stable revenue retention rates [5] - The management acknowledged market concerns regarding AI disruption but emphasized the proprietary nature of their business as a competitive advantage [7] - The outlook for the Intellectual Property segment is increasingly positive, with expectations of returning to organic revenue growth [16] Other Important Information - The company has launched a process to sell its Life Sciences & Healthcare business, which is expected to focus operational execution on A&G and IP segments [6][12] - The company has introduced 12 major products and AI-powered features in 2025, strengthening its market position [11] Q&A Session Summary Question: Can you talk about your monetization model for your subscriptions and for the new AI products? - The company continues to use AI to protect and grow its subscription revenue, with upsell opportunities for existing products and a shift towards more subscription-based models [34][36] Question: Can you explain the 97% of revenue coming from proprietary data? - The company clarified that 97% of its business derives from proprietary data, with a significant portion coming from information services and enterprise software [42][43] Question: What were the key considerations for initiating a sale process for the Life Sciences and Healthcare business? - The decision was based on the goal of creating shareholder value and focusing on operational execution across A&G and IP segments [50][51] Question: What will it take to return the IP segment to organic revenue growth? - Management highlighted the importance of product innovation and market recovery as key drivers for returning the IP segment to growth [62][66] Question: Can you provide color on capital allocation priorities? - The company plans to focus on deleveraging this year while also considering stock buybacks, given the attractive free cash flow yield [69][70] Question: Can you speak to the composition of ACV and recurring revenue growth in 2025? - The company noted that improvements in ACV and recurring organic growth were primarily driven by volume rather than price realization [72][73]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [15] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [15] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [15] - Free cash flow for the full year reached $365 million, reflecting a 2% growth over the prior year [19] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [10] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [12] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [12] Market Data and Key Metrics Changes - The company reported stable revenue retention rates of 93% and expects organic annual contract value growth of 2%-3% for 2026 [13][21] - The anticipated decline in revenue due to strategic disposals is expected to be approximately $100 million, with organic recurring revenue mix improving to between 88% and 90% [21][23] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance emphasis on the A&G and IP markets and strengthen its balance sheet [5][49] - The AI strategy is centered on leveraging proprietary data and domain expertise to enhance product offerings, with 97% of revenue derived from proprietary assets [6][42] - The company aims to maximize shareholder value through portfolio simplification and disciplined capital allocation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued improvement in key financial metrics and organic growth acceleration supported by AI innovation [14][13] - The company acknowledges market concerns regarding AI disruption but believes its proprietary business model provides a significant competitive advantage [5][6] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to create shareholder value and allow for a more focused operational execution across A&G and IP segments [5][49] - The company plans to continue investing in product innovation while also focusing on cost efficiencies to improve capital spending [27] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management confirmed that the subscription model is evolving, with a focus on upselling AI innovations and transitioning to more subscription-based products [32][33] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with a significant portion from information services and enterprise software [42] Question: Considerations for selling Life Sciences and Healthcare business - The decision was based on the goal of creating shareholder value and focusing on the A&G and IP segments, which have synergies [48][49] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the two segments, which can enhance innovation and operational execution [53][56] Question: Returning the IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing strong assets and a focus on innovation and execution [60][62] Question: Capital allocation priorities - Management indicated a focus on deleveraging while also considering stock buybacks, emphasizing the attractive free cash flow yield [68][70] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [72][75]

Core Insights - The French National Centre for Scientific Research (CNRS) announced it will stop accessing the Web of Science database from January 1, 2026, as part of its commitment to open science and changing the evaluation of scientific work [1][7][9] Group 1: Open Science Policy - CNRS has been promoting open science since the release of its first Open Science Roadmap in 2019, opposing quantitative evaluations based on bibliometric indicators in favor of qualitative assessments [3][9] - The decision to discontinue Web of Science is a significant step in CNRS's open science policy, aiming to enhance the quality and ethics of scientific evaluation [4][10] Group 2: Financial Implications - By stopping the subscription to Web of Science, CNRS will save €1.4 million annually, which will be reinvested into open science initiatives, particularly the development of open databases [5][11] Group 3: Transition to OpenAlex - CNRS is encouraging researchers to transition to OpenAlex, which offers greater visibility for non-English journals and a broader range of indexed journals compared to Web of Science [5][11] - OpenAlex aims to address the coverage gaps in various fields, such as humanities, social sciences, computer science, and mathematics, where Web of Science has been lacking [5][11] Group 4: Challenges and Future Directions - While leaving Web of Science may temporarily hinder the ability to make standardized comparisons between institutions and researchers, CNRS acknowledges the need to establish new principles for such evaluations [6][12] - CNRS is actively working to improve OpenAlex's metadata management to enhance its potential and is confident that it will soon meet the needs of researchers [6][12] - The organization aims to regain autonomy in scientific decision-making and enhance transparency through open tools, inviting partners to also distance themselves from Web of Science [6][12]

Core Insights - China's scientific research influence is rapidly increasing, reshaping the global scientific landscape, as highlighted by the analysis from Clarivate Analytics based on 25 years of citation data from the Web of Science database [1] - The United States is experiencing a gradual decline in its traditional position as a research powerhouse and collaboration center due to various policies that have negatively impacted its research environment [1] - Over the past decade, China's domestic research output has doubled, making it the largest producer of academic papers globally by 2020, with expectations to lead in citation metrics as well [1] Group 1 - The collaboration between China and Europe in scientific research is strengthening, while the collaboration between China and the U.S. has slowed down since 2019 due to restrictions on academic exchanges and China's focus on enhancing its own research capabilities [2] - The overall global research collaboration is on the rise, with high-impact research increasingly stemming from multilateral cooperation [1][2] - The decline in U.S. research output and citation influence has been ongoing for several years, exacerbated by the pandemic, with a notable decrease in citation impact observed since 2018 [1] Group 2 - Experts suggest that the global research collaboration network is undergoing a restructuring, influenced by the adjustments in U.S.-China relations, with China aiming to build a multipolar scientific system while enhancing its domestic capabilities [2] - The shift in the dynamics of international scientific collaboration may hinder the open exchange of information, particularly if the U.S. imposes further restrictions under the guise of national security and economic competitiveness [2]

Summary of Clarivate Conference Call Company Overview - **Company**: Clarivate (NYSE: CLVT) - **Date of Conference**: November 19, 2025 Key Industry Insights - **Industry Focus**: Information services, particularly in academic, life sciences, and intellectual property (IP) sectors - **Core Technology**: Emphasis on proprietary data and AI integration Core Points and Arguments 1. **Generative AI Impact**: Clarivate views generative AI as an opportunity rather than a threat, leveraging its proprietary data that cannot be replicated by public AI systems [4][5][6] 2. **Proprietary Data**: The company emphasizes its unique data assets across segments, including bibliometric databases and proprietary analytics, which are deeply embedded in client workflows [5][6][7] 3. **AI Innovations**: Clarivate is actively deploying AI across its products, enhancing existing offerings and introducing new AI-driven products, such as RiskMark and Web of Science Research Intelligence [8][15] 4. **Investment Strategy**: Current capital spending is deemed adequate, with a focus on AI-driven product development and operational efficiencies expected to enhance margins in the future [11][12] 5. **Subscription Growth**: The company has increased its subscription revenue from 80% to 88% of organic revenue, with plans to reach 90% [16][18] 6. **Renewal Rates**: Improvement in renewal rates from 92% to 93% attributed to product investments and enhanced customer success initiatives [14][20] 7. **Market Growth Projections**: Clarivate anticipates growth in the ANG market at 3%-4%, with life sciences showing mid-single-digit growth potential [21][22][30] 8. **IP Market Recovery**: New patent filings increased by 5%, indicating a recovery in the IP market, which is expected to benefit Clarivate's annuity business [24][25] 9. **Competitive Positioning**: Clarivate maintains a unique market position with a comprehensive suite of products that competitors cannot match [26] Additional Important Insights - **Geographic Stability**: The company reports stable budgets across major geographies, with encouraging performance in North America [29] - **Life Sciences Transition**: The life sciences segment is transitioning towards a higher percentage of subscription revenue, currently at 85% [32] - **Cash Flow and Capital Allocation**: Clarivate has robust free cash flow generation, with balanced capital allocation strategies including stock repurchases and debt reduction [36][37] This summary encapsulates the key points discussed during the Clarivate conference call, highlighting the company's strategic focus on AI, proprietary data, and subscription growth while navigating market dynamics and competitive positioning.